Dr. Martins on Patient Selection for Nivolumab in NSCLC

Renato G. Martins, MD, MPH
Published: Monday, Feb 15, 2016



Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).

PD-L1 expression is often debated as a biomarker for patients with NSCLC. However, Martins believes there are no patients who are not eligible to receive nivolumab, as durable responses have been observed in patients who are PD-L1–negative.

This reinforces the concept that PD-L1 may be a biomarker, but should not be used as the biomarker to determine how patients will respond to nivolumab.


Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).

PD-L1 expression is often debated as a biomarker for patients with NSCLC. However, Martins believes there are no patients who are not eligible to receive nivolumab, as durable responses have been observed in patients who are PD-L1–negative.

This reinforces the concept that PD-L1 may be a biomarker, but should not be used as the biomarker to determine how patients will respond to nivolumab.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x